Importantly, clinicopathological analyses revealed that elevated STC2 expression was significantly associated with poor prognosis in patients with HCC, whereas increased MAOB levels were likely correlated with a favourable prognosis with a log-rank P value of 0.062 (Fig. 8I, J). This evidence concerns the gene STC2 and hepatocellular carcinoma.